Skip to content
Search

Latest Stories

Pharmacies continue to face cost pressures despite increased activity - Christie & Co report

Pharmacies continue to face cost pressures despite increased activity - Christie & Co report

Employment cost pressures continue to be a significant challenge for pharmacy businesses and are expected to persist throughout this financial year

Pharmacy businesses continue to face rising cost pressures despite increased services and dispensing activity, according to Christie & Co's Pharmacy Market Review 2024 report.

The report revealed that in the 12 months leading up to March 2024, dispensing activity across England increased by 8%. This contributed to a rise in the average number of items dispensed by community pharmacies, reaching 8,565 items per month.


In addition to this year’s rollout of the Pharmacy First Scheme, 9,261 pharmacies in England undertook an average of 336,525 New Medicines Services per month, equating to an annual total of 4,038,300.

However, the report found that, despite seeing increased turnover through additional activities, remuneration under the 5-year deal was “unable to offset the increased cost pressures the sector has experienced.”

Analysis of the broker’s transactional and valuation data for the last 12 months showed the average combined gross margins fell by 1.7% to 31.9%.

The report noted that, without the increased service offerings they generated, overall margins would have declined further.

Jonathan Board, Director – Pharmacy at Christie & Co, said: “With any operational efficiencies that can be delivered having now been delivered, the continued cost pressures are unsustainable, a situation which, without an urgent funding boost, will lead to further distress in the sector.”

“With the recent news that clarity will not be seen until after the Chancellor’s Autumn Statement, contractors in England will have to wait to see whether any proposed increase will offer respite for the remainder of the financial year and how much this will offset further National Living Wage increases anticipated in April 2025.”

Employment cost pressures remain one of the key issues impacting pharmacy businesses. With the 9.8% increase in the National Living Wage in April 2024, these pressures are expected to persist throughout the remainder of the financial year.

The report also highlighted that price concessions continue to challenge the sector.

In April 2024, the Department for Health and Social Care imposed changes to its approach to concession pricing without prior testing or consultation. Community Pharmacy England has strongly opposed these changes, warning that putting further pressure on pharmacies to dispense at a loss will have profound consequences for the sector, patients, and the primary care system.

Jonathan stated that while cost pressures are likely to persist in the foreseeable future, there remains a strong market appetite for “those businesses that can weather the storm.”

“Following the glut of corporate disposals over recent years, we anticipate that the market will return to some sense of normality as potential purchasers eye up more traditional independent pharmacy opportunities. Market appetite in England will be tempered by the outcome of the much-needed funding settlement negotiations,” he added.

The report indicated that in the year ending 31 March 2024, the UK pharmacy market experienced a decline of 3.5%, with 505 pharmacies removed from the register. This brought the total number of pharmacies in England, Scotland, Wales, and Northern Ireland down to 13,822.

Most closures occurred within corporate estates, with Rowlands reporting a 15.8% decrease in its network and Boots experiencing a 13.2% reduction.

Supermarket chains such as Tesco, Asda, and Morrisons also saw minor reductions in the number of pharmacies they operated.

In contrast, Well Pharmacy expanded its branch network by 3.8%, increasing its total to 761 pharmacies, largely due to the acquisition of 42 pharmacies from the Norchem Group.

The corporate market share was significantly affected by the complete removal of the LloydsPharmacy brand from the high street, as its owner, AURELIUS, completed its national divestment programme and exited the sector.

During its two-year ownership of LloydsPharmacy, AURELIUS oversaw the closure of 1,349 corporate pharmacy branches.

In the first half of 2024, the broker successfully completed 95 transactions, with 22% sold to first-time buyers, 13% to independent contractors, 22% to small independents, 13% to regional multiples, and 30% to large group operators.

Over the past 12 months, online pharmacies have gained significant attention, particularly due to the merger of LloydsDirect and Pharmacy2U announced in autumn 2023.

The report revealed an 11% increase in dispensing volumes among the top seven online pharmacies, totaling 36,108,103 dispensed items by the end of March 2024.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less